Cell Genesys Ends Prostate Cancer Trial Over Deaths
wrote an interesting post today on
Here’s a quick excerpt
The drugmaker halted a late-stage of its GVAX prostate cancer therapy after 20 more deaths were reported in patients on its treatment versus a placebo, sending its shares plummeting more than 75 percent to an all-time low, Reuters reports. The cause for the “imbalance in deaths” has not yet been identified, but the biotech says an independent committee, which pointed out the death mismatch, reported no new safety issues for the therapy. One of two trials that were conducted had enrolled 408 pa
Read the rest of this great post here